Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.55 |
| ▸ | CD74 | P04233 | 1/20 | 0.48 |
| ▸ | SPTLC1 | O15269 | 1/20 | 0.45 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981482 | 0.88 | CTSS (0.57) | CTSSKCNK3CD74SPTLC1TRPM2 | |
| SCHEMBL2973887 | 0.88 | CTSS (0.56) | CTSSKCNK3CD74SPTLC1TRPM2 | |
| SCHEMBL5127331 | 0.82 | CTSS (0.48) | CTSSKCNK3BRD4CREBBP | |
| SCHEMBL2976436 | 0.81 | CTSS (0.58) | CTSSKCNK3CD74 | |
| SCHEMBL4719347 | 0.80 | CTSS (0.70) | CTSSCD74 | |
| SCHEMBL5534130 | 0.79 | CTSS (0.83) | CTSSCD74 | |
| SCHEMBL2982361 | 0.79 | CTSS (0.60) | CTSSCD74 | |
| SCHEMBL2975019 | 0.79 | CTSS (0.57) | CTSSKCNK3CD74 | |
| SCHEMBL29844211 | 0.78 | CTSS (0.46) | CTSSKCNK3SPTLC1TRPM2BRD4 | |
| SCHEMBL2074354 | 0.78 | KCNK3 (0.60) | CTSSKCNK3TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7589202-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080300255-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-12-04 | — | — | US | disclosed |
| US-20080293732-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-11-27 | — | — | US | disclosed |
| US-7452890-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1315490-B1 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7429591-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7417046-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7393850-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7388011-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20030078419-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-10 | — | — | US | disclosed |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-08-22 | — | — | US | disclosed |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-05-09 | — | — | US | disclosed |
| US-20020040020-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002020012-A2 | METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020011-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002014315-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293732-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | CTSS 1/4885KCNK3 2071/4885CD74 80/4885 |
| US-20030078419-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | CTSS 1/4885KCNK3 2182/4885CD74 125/4885 |
| US-20080300255-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | CTSS 1/4885KCNK3 2071/4885CD74 80/4885 |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | CTSS 294/4885KCNK3 346/4885CD74 519/4885 |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | CTSS 294/4885KCNK3 346/4885CD74 519/4885 |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | CTSS 294/4885KCNK3 346/4885CD74 519/4885 |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | CTSS 294/4885KCNK3 346/4885CD74 519/4885 |
| US-20020040020-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | CTSS 1/4885KCNK3 2182/4885CD74 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.